Abstract: Provided here are nuclear receptor 4A agonists and methods of use for treatment of an infectious disease or an inflammation-related disease. These agonists include 3-(adamantan-1-yl)-1-(2-hydroxy-2-phenylpropyl)urea (available at Life Chemicals as F6279-0659), N-(3-acetylphenyl)-5,6,7,8-tetrahydronaphthalene-2-carboxamide (available at Life Chemicals as F0537-0485), N-[(1-hydroxy-2,3-dihydro-1H-inden-1-yl)methyl]naphthalene-1-carboxamide (available at Life Chemicals as F5857-5371), 3,4-difluoro-N-[(2-hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)methyl]benzamide (available at Life Chemicals as F6414-1064), N-(3-hydroxy-3-phenylpropyl)naphthalene-1-carboxamide (available at Life Chemicals as F5857-6887), N-(2-hydroxy-3-phenylpropyl)naphthalene-1-carboxamide (available at Life Chemicals as F6200-1091) or a pharmaceutically acceptable salt thereof.

Abstract: Methods of inhibiting LSD1 activity by administering a compound that binds to SWIRM domain of LSD1 and inhibits LSD1 activity; methods of inhibiting LSD1 activity where the compound interacts with L547 residue within the hydrophobic pocket of LSD1; methods of determining the efficacy of a drug to be an LSD1 inhibitor wherein a candidate drug is screened to determine whether it binds to SWIRM domain of LSD1 and inhibits LSD1 activity.